The Journal of Heart and Lung Transplantation
Volume 28, Issue 7 , Pages 710-717 , July 2009

Increased Number of Circulating Progenitor Cells After Implantation of Ventricular Assist Devices

  • Athanassios Manginas, MD

      Affiliations

    • Department of Cardiology, Onassis Cardiac Surgery Center, Athens, Greece
    • Corresponding Author InformationReprint requests: Athanassios Manginas, MD, FACC, FESC, Onassis Cardiac Surgery Center, Department of Cardiology, 356 Sygrou Ave, Kallithea, Athens, 176 74, Greece. Telephone: +30-210-949-3235. Fax: +30-210-949-3235
    • ,
  • Anastasia Tsiavou, PhD

      Affiliations

    • Cardiothoracic Surgery & Heart Transplantation, Onassis Cardiac Surgery Center, Athens, Greece
    • ,
  • Petros Sfyrakis, MD

      Affiliations

    • Molecular Immunopathology and Histocompatibility Laboratory, Onassis Cardiac Surgery Center, Athens, Greece
    • ,
  • Gregory Giamouzis, MD

      Affiliations

    • Department of Cardiology, Onassis Cardiac Surgery Center, Athens, Greece
    • ,
  • Loukas Tsourelis, MD

      Affiliations

    • Molecular Immunopathology and Histocompatibility Laboratory, Onassis Cardiac Surgery Center, Athens, Greece
    • ,
  • Evangelos Leontiadis, MD

      Affiliations

    • Department of Cardiology, Onassis Cardiac Surgery Center, Athens, Greece
    • ,
  • Dimitrios Degiannis, MD, PhD

      Affiliations

    • Cardiothoracic Surgery & Heart Transplantation, Onassis Cardiac Surgery Center, Athens, Greece
    • ,
  • Dennis V. Cokkinos, MD

      Affiliations

    • Department of Cardiology, Onassis Cardiac Surgery Center, Athens, Greece
    • ,
  • Petros A. Alivizatos, MD

      Affiliations

    • Molecular Immunopathology and Histocompatibility Laboratory, Onassis Cardiac Surgery Center, Athens, Greece

Received 28 November 2008 ,Revised 17 March 2009 ,Accepted 7 April 2009.

References 

  1. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med. 2001;345:1435–1443
  2. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275:964–967
  3. Urbich C, Heeschen C, Aicher A, Dernbach E, Zeiher AM, Dimmeler S. Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. Circulation. 2003;108:2511–2516
  4. Urbich C, Aicher A, Heeschen C, et al. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol. 2005;39:733–742
  5. Ingram DA, Caplice NM, Yoder MC. Unresolved questions, changing definitions, and novel paradigms for defining endothelial progenitor cells. Blood. 2005;106:1525–1531
  6. Peichev M, Naiyer AJ, Pereira D, et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood. 2000;95:952–958
  7. Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res. 2004;95:343–353
  8. Yin AH, Miraglia S, Zanjani ED, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood. 1997;90:5002–5012
  9. Laufs U, Werner N, Link A, et al. Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation. 2004;109:220–226
  10. Wojciech W, RataJczak M, Tendera M. Intereukin-8:more on the mechanisms of progenitor cells mobilization in acute coronary syndromes. Eur Heart J. 2006;27:1013–1015
  11. Leone AM, Rutella S, Bonanno G, et al. Endogenous G-CSF and CD34+ cell mobilization after acute myocardial infarction. Int J Cardiol. 2006;111:202–208
  12. Asahara T, Takahashi T, Masuda H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 1999;18:3964–3972
  13. George J, Goldstein E, Abashidze A, et al. Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase-dependent manner. Cardiovasc Res. 2005;68:299–306
  14. Dimmeler S, Aicher A, Vasa M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest. 2001;108:391–397
  15. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003;348:593–600
  16. Gill M, Dias S, Hattori K, et al. Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells. Circ Res. 2001;88:167–4
  17. Goette A, Jentsch-Ullrich K, Lendeckel U, et al. Effect of atrial fibrillation on hematopoietic progenitor cells: a novel pathophysiological role of the atrial natriuretic peptide?. Circulation. 2003;108:2446–2449
  18. Massa M, Rosti V, Ferrario M, et al. Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood. 2005;105:199–206
  19. Schmidt-Lucke C, Rössig L, Fichtlscherer S, et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation. 2005;111:2981–2987
  20. Valgimigli M, Rigolin GM, Fucili A, et al. CD34+ and endothelial progenitor cells in patients with various degrees of CHF. Circulation. 2004;110:1209–1212
  21. Fadini GP, Coracina A, Baesso I, et al. Peripheral blood CD34+KDR+ endothelial progenitor cells are determinants of subclinical atherosclerosis in a middle-aged general population. Stroke. 2006;37:2277–2282
  22. Bland JM, Douglas GA. Calculating correlation coefficients with repeated observations: Part 2--correlation between subjects. BMJ. 1995;310:633
  23. Rafii S, Oz MC, Seldomridge JA, et al. Characterization of hematopoietic cells arising on the textured surface of left ventricular assist devices. Ann Thorac Surg. 1995;60:1627–1632
  24. Iversen PO, Woldbaek PR, Tønnessen T, Christensen G. Decreased hematopoiesis in bone marrow of mice with CHF. Am J Physiol Regul Integr Comp Physiol. 2002;282:R166–R172
  25. Nonaka-Sarukawa M, Yamamoto K, Aoki H, et al. Circulating endothelial progenitor cells in CHF. Int J Cardiol. 2007;119:344–348
  26. Hampton CR, Verrier ED. Systemic consequences of ventricular assist devices: alterations of coagulation, immune function, inflammation, and the neuroendocrine system. Artif Organs. 2002;26:902–908
  27. Wohlschlaeger J, Schmitz KJ, Schmid C, et al. Reverse remodeling following insertion of left ventricular assist devices (LVAD): a review of the morphological and molecular changes. Cardiovasc Res. 2005;68:376–386
  28. Jahanyar J, Youker KA, Torre-Amione G, et al. Increased expression of stem cell factor and its receptor after left ventricular assist device support: a potential novel target for therapeutic interventions in heart failure. J Heart Lung Transplant. 2008;27:701–709
  29. Perin EC, Dohmann HF, Borojevic R, et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation. 2003;107:2294–2302
  30. Yoshioka T, Ageyama N, Shibata H, et al. Repair of infarcted myocardium mediated by transplanted bone marrow-derived CD34+ stem cells in a nonhuman primate model. Stem Cells. 2005;23:355–364
  31. Assmus B, Schächinger V, Teupe C, et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation. 2002;106:3009–3017
  32. Tse HF, Kwong YL, Chan JK, Lo G, Ho CL, Lau CP. Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet. 2003;361:47–49
  33. Stamm C, Westphal B, Kleine HD, et al. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet. 2003;361:45–46
  34. Wollert KC, Meyer GP, Lotz J, et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet. 2004;364:141–148
  35. Nissen NN, Polverini PJ, Koch AE, et al. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol. 1998;152:1445–1452
  36. Scheubel RJ, Zorn H, Silber RE, et al. Age-dependent depression in circulating endothelial progenitor cells in patients undergoing coronary artery bypass grafting. J Am Coll Cardiol. 2003;42:2073–2080
  37. Fadini GP, de Kreutzenberg SV, Coracina A, et al. Circulating CD34+ cells, metabolic syndrome, and cardiovascular risk. Eur Heart J. 2006;27:2247–2255
  38. Popa ER, Harmsen MC, Tio RA, et al. Circulating CD34+ progenitor cells modulate host angiogenesis and inflammation in vivo. J Mol Cell Cardiol. 2006;41:86–96
  39. Maisel AS, Krishnaswamy P, Nowak RM, et al. Breathing Not Properly Multinational Study Investigators (Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure). N Engl J Med. 2002;347:161–167
  40. Rothenburger M, Wichter T, Schmid C, et al. Aminoterminal pro type B natriuretic peptide as a predictive and prognostic marker in patients with chronic heart failure. J Heart Lung Transplant. 2004;23:1189–1197
  41. Nakagawa O, Ogawa Y, Itoh H, et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy (Evidence for brain natriuretic peptide as an “emergency” cardiac hormone against ventricular overload). J Clin Invest. 1995;96:1280–1287
  42. Bruggink AH, de Jonge N, van Oosterhout MF, et al. Brain natriuretic peptide is produced both by cardiomyocytes and cells infiltrating the heart in patients with severe heart failure supported by a left ventricular assist device. J Heart Lung Transplant. 2006;25:174–180
  43. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J. 1998;135:825–832
  44. Sodian R, Loebe M, Schmitt C, et al. Decreased plasma concentration of brain natriuretic peptide as a potential indicator of cardiac recovery in patients supported by mechanical circulatory assist systems. J Am Coll Cardiol. 2001;38:1942–1949
  45. Milting H, EL Banayosy A, Kassner A, et al. The time course of natriuretic hormones as plasma markers of myocardial recovery in heart transplant candidates during ventricular assist device support reveals differences among device types. J Heart Lung Transplant. 2001;20:949–955
  46. Kemperman H, van den Berg M, Kirkels H, de Jonge N. B-type natriuretic peptide (BNP) and N-terminal proBNP in patients with end-stage heart failure supported by a left ventricular assist device. Clin Chem. 2004;50:1670–1672
  47. Heeschen C, Lehmann R, Honold J, et al. Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation. 2004;109:1615–1622
  48. Kissel CK, Lehmann R, Assmus B, et al. Selective functional exhaustion of hematopoietic progenitor cells in the bone marrow of patients with postinfarction heart failure. J Am Coll Cardiol. 2007;49:2341–2349

PII: S1053-2498(09)00228-9

doi: 10.1016/j.healun.2009.04.006

The Journal of Heart and Lung Transplantation
Volume 28, Issue 7 , Pages 710-717 , July 2009

Article Tools

* Image Usage & Resolution